Efficacy of Sumatriptan/PlaceboversusSumatrip-tan/Propofol Combination in Acute Migraine; a Random-ized Clinical Trial

Migraine headaches can cause severe pain for patients and lead them to multiple visits to theemergency department (ED). This study aimed to evaluate the efficacy of propofol + sumatriptan combinationin comparison with sumatriptan alone in the management of acute migraine headaches.

This triple-blind clinical trial involved patients who referred to two emergency departments with acute migraine headaches.Patients were randomly assigned to control (sumatriptan and placebo) or intervention (propofol and sumatrip-tan) groups for comparison of the efficacy and side effects of treatment.

In this study, 60 patients wereincluded whose mean age was 31±8.8 years, and headaches were more common among women. After 30 and60 minutes from the beginning of treatment, the mean pain score reduction in the intervention group was sig-nificantly greater than that in the control group (p=0.012, p=0.024). In addition, the rate of chest tightness inthe control group was significantly higher than the intervention group. The absolute risk reduction of adverseevents (Chest tightness, Bradycardia, hypotension, and etc.), in patients with acute migraine headache takingpropofol and sumatriptan treatment, was 32.18% (95% CI: 8.02 – 56.35).

This study supports theuse of propofol for treatment of acute migraine headaches and shows that combining sumatriptan with propofolis more effective in relieving migraine headaches and the associated symptoms than using sumatriptan alone.However, more studies with longer follow-ups are still needed.